Pulse Biosciences (PLSE) Expected to Post Quarterly Earnings on Thursday

Pulse Biosciences (NASDAQ:PLSE) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Pulse Biosciences to announce earnings of ($0.2933) per share and revenue of $0.5330 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.05. The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.25 million. On average, analysts expect Pulse Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulse Biosciences Trading Up 1.2%

Shares of NASDAQ:PLSE opened at $38.17 on Wednesday. The stock has a fifty day simple moving average of $28.13 and a two-hundred day simple moving average of $23.17. The stock has a market capitalization of $2.64 billion, a price-to-earnings ratio of -34.70 and a beta of 1.61. Pulse Biosciences has a 12-month low of $12.56 and a 12-month high of $38.90.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, CEO Paul A. Laviolette bought 15,000 shares of Pulse Biosciences stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $19.69 per share, with a total value of $295,350.00. Following the acquisition, the chief executive officer owned 15,000 shares in the company, valued at approximately $295,350. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert W. Duggan bought 660,233 shares of Pulse Biosciences stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $19.69 per share, with a total value of $12,999,987.77. Following the acquisition, the director owned 48,211,433 shares in the company, valued at approximately $949,283,115.77. This represents a 1.39% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 74.00% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Several large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its stake in shares of Pulse Biosciences by 31.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 22,453 shares of the company’s stock worth $308,000 after acquiring an additional 5,322 shares during the period. Wells Fargo & Company MN lifted its position in Pulse Biosciences by 62.3% during the fourth quarter. Wells Fargo & Company MN now owns 22,149 shares of the company’s stock valued at $304,000 after purchasing an additional 8,502 shares during the period. Norges Bank bought a new position in Pulse Biosciences during the second quarter valued at approximately $302,000. Deutsche Bank AG boosted its holdings in Pulse Biosciences by 33.0% in the fourth quarter. Deutsche Bank AG now owns 21,516 shares of the company’s stock worth $295,000 after purchasing an additional 5,335 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in Pulse Biosciences by 23.2% in the fourth quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock worth $291,000 after purchasing an additional 3,991 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group started coverage on Pulse Biosciences in a report on Thursday, June 4th. They set a “buy” rating and a $32.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Finally, Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Pulse Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $32.33.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.